Clinical Trial: The BENEFIT Trial - Evaluation of the Use of Benznidazole in the Treatment of Chronic Chagas Disease.

This study is currently recruiting patients.

Sponsors and Collaborators: McMaster University
Dante Pazzanese Institute
Information provided by: McMaster University


The purpose of this study is to determine if 60 days with treatment with an antiparasital drug (benznidazole) could prevent the development of cardiac disease in patients with Chagas Disease.
Condition Intervention Phase
Chagas Disease
Chronic Heart disease
 Drug: Benznidazole
Phase III

MedlinePlus related topics:  Chagas Disease;   Pfiesteria Infections

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study

Official Title: Benznidazole Evaluation for Interrupting Trypanosomiasis - the BENEFIT Trial

Further Study Details: 
Primary Outcomes: the first occurrence of any of the following clinically significant outcomes:; 1. Death; 2. Cardiac arrest, requiring defibrillator or cardioversion; 3. Documented sustained ventricular tachycardia requiring cardioversion; 4. New development of symptomatic congestive heart failure; 5. Pacemaker or implantable cardiac defibrillator implantation; 6. Stroke or any other thromboembolic event in patients with no prior thromboembolic phenomena
Secondary Outcomes: 1. New development of any of the following echo changes clinically indicated or done for the trial: segmental wall motion abnormalities, ventricular aneurysm, reduction in LV ejection fraction > 5%; increase in LVDD > 5.0 mm compared with baseline; 2. New 12 lead ECG alterations (complete bundle branch block; fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc; 3. Progression of NYHA functional class by at least one category.; 4. Evaluation of safety (adverse events: dermatitis, peripheral neuropathy, gastro-intestinal intolerance; leucopenia (2500 x 10 9 L), tolerance and adherence to treatment
Expected Total Enrollment:  3000

Study start: November 2004;  Expected completion: December 2011
Last follow-up: December 2010;  Data entry closure: December 2010

A randomized double-blind controlled clinical trial of Benznidazole in patients with chronic Chaga''''s heart disease. Chagas disease has 3 phases: acute, indetermined and chronic phases.There are no clinical trials up to date that have investigated the use of antiparasitic drugs in patients that are in the chronic phase. This study will evaluate the efficacy and safety of benznidazole (an antiparasitic drug) in patients with Chronic Chagas heart disease. It will evaluate if 60 days of drug treatment will reduce mortality and morbidity in patients with Chronic Chagas heart disease.


Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers


Inclusion Criteria: Consenting patients (between 18 and 65 years of age)with serological evidence of Chagas infection (any combination of 2 positive tests) and that have one or more of the following:

  • Abnormal Electrocardiogram with at least two components (complete RBBB or LBBB; left anterior or posterior fascicular block; ventricular premature beat; first degree AV block; mobitz type I AV block; sinus bradycardia; primary ST-T changes; abnormal Q waves; low voltage QRS; or atrial fibrillation)
  • Abnormal ECG (Mobitz type II, advanced or third degree AV block)
  • Increased cardiothoracic ratio (> 0.50)
  • Complex ventricular arrythmias on 24hr ambulatory ECG monitoring
  • Evidence of regional wall motion abnormality or reduced global left ventricular systolic function or increased left ventricular and diastolic diameter on 2D-Echo.

Exclusion Criteria: Patients will be excluded if having:

  • NYHA heart failure class IV or decompensated heart failure
  • Evidence of concomitant CAD or other etiology of dilated cardiomyopathy
  • Previous treatment with antitrypanosomal agents or an accepted indication for antiparasitic therapy
  • Inability to comply with follow-up visits
  • History of severe alcohol abuse within 2 years
  • Known chronic renal or hepatic insufficiency
  • Pregnancy or breast feeding
  • Megaesophagus with swallowing impairment
  • Other severe disease significantly curtailing life expectancy

Location and Contact Information

Please refer to this study by identifier  NCT00123916

Carlos Morillo, MD, PhD      1-905-527-4322  Ext. 44386
Alvaro Avezum, MD,PhD      55-11-5085-4204

      CenDIE, Buenos Aires,  Argentina; Not yet recruiting
Sergio Sosa-Estani, MD  54-11-43312536 
Sergio Sosa-Estani, MD,  Principal Investigator

      Dante Pazzanese Instituto de Cardiologia, Sao Paulo,  04012-180,  Brazil; Recruiting
Alvaro Avezum, MD  011-55-5085-4204 
Helio Guimaraes, MD  011-55-5085-4204 
Abilio Fragata, MD,  Principal Investigator

Brazil, Sao paulo
      FAEPA-Faculdade de Medicina de Ribeirao Preto, Ribeirao Preto,  Sao paulo,  14090-100,  Brazil; Recruiting
Jose Marin-Neto, MD, PhD  011-55-16-633-1040 
Lia Chinthia  011-55-16-633-1040 
Marcus Simoes, MD,  Principal Investigator

Canada, Ontario
      Population Health Research Institute - McMaster University, Hamilton,  Ontario,  L8L 2X2,  Canada; Recruiting
Barbara Ramos, PhD  1-905-527-4322  Ext. 44515 
Carlos Morillo, MD,PhD,  Principal Investigator

Study chairs or principal investigators

Carlos Morillo,  Principal Investigator,  McMaster University   

More Information

Study ID Numbers:  BEN01; CONEP-11394
Record last reviewed:  June 2005
Last Updated:  July 25, 2005
Record first received:  July 25, 2005 Identifier:  NCT00123916
Health Authority: Brazil: Committee of Ethics in Research processed this record on 2005-07-26


Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us